- Home
- CCM vs SNSE Comparison
CCM vs SNSE Comparison
Compare CCM & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CCM | SNSE |
|---|---|---|
| Founded | 1997 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.9M | 12.2M |
| IPO Year | 2009 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CCM | SNSE |
|---|---|---|
| Price | $4.00 | $32.21 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $65.00 |
| AVG Volume (30 Days) | 1.7K | ★ 31.5K |
| Earning Date | 05-08-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.18 | $0.26 |
| 52 Week High | $10.77 | $36.76 |
Technical Indicators
Market Signals| Indicator | CCM | SNSE |
|---|---|---|
| Relative Strength Index (RSI) | 56.17 | 54.20 |
| Support Level | $3.58 | $7.94 |
| Resistance Level | $4.14 | $35.94 |
| Average True Range (ATR) | 0.06 | 2.70 |
| MACD | 0.01 | -0.04 |
| Stochastic Oscillator | 68.63 | 64.24 |
Price Performance
Historical ComparisonAbout CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).